{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:23:07Z","timestamp":1787764987350,"version":"build-2784847793"},"reference-count":120,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Difficult-to-treat mycobacterial infections are increasing globally. There is an urgent need of new treatment alternatives for multidrug-resistant\n                    <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                    (MTB), as well as nontuberculous mycobacteria such as the\n                    <jats:italic toggle=\"yes\">Mycobacterium abscessus<\/jats:italic>\n                    complex (MABC) and\n                    <jats:italic toggle=\"yes\">Mycobacterium avium<\/jats:italic>\n                    complex (MAC). Recently, new carbapenems and combinations of carbapenems with \u03b2-lactamase inhibitors have become available, but activity data\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    against mycobacteria are so far scarce. Therefore, we performed a systematic review collating the minimum inhibitory concentrations (MICs) of carbapenems, with or without a \u03b2-lactamase inhibitors for MTB, MABC, and MAC. The databases PubMed and Web of Science were searched for the relevant articles in English up until September 21, 2022. Screening of studies was performed by two independent reviewers. MIC data by recommended methods with at least five individual MICs were included. Data were reported as MIC range, MIC\n                    <jats:sub>50<\/jats:sub>\n                    , modal MIC, and\/or histograms when individual MICs were available. The study protocol was registered at PROSPERO (CRD42021258537). After screening, a total of 75 studies with MIC data for carbapenems with or without \u03b2-lactamase inhibitors were included in the review. For MTB, the oral carbapenem tebipenem combined with the \u03b2-lactamase inhibitor clavulanic acid resulted in the most significant reduction of MICs. For MABC, the addition of avibactam to tebipenem resulted in a 64-fold reduction of modal MIC. Data were insufficient for the analysis of MAC. Carbapenems, and in particular the novel oral compound tebipenem, in combination with clavulanic acid for MTB and avibactam for MABC may be an untapped potential for difficult-to-treat mycobacterial infections.\n                  <\/jats:p>","DOI":"10.4103\/ijmy.ijmy_131_23","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:00:08Z","timestamp":1741140008000},"page":"211-225","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["The In vitro Activity of Carbapenems Alone and in Combination with \u03b2-lactamase Inhibitors against Difficult-to-treat Mycobacteria; Mycobacterium tuberculosis, Mycobacterium abscessus, and Mycobacterium avium Complex: A Systematic Review"],"prefix":"10.4103","volume":"12","author":[{"given":"Viktoria","family":"Andersson","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital, Solna, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Fr\u00f6berg","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital, Solna, Stockholm, Sweden"},{"name":"Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, Solna, Stockholm, Sweden"},{"name":"Department of Clinical Microbiology, Karolinska University Hospital, Solna, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Naestholt","family":"Dahl","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Center for Global Health, Aarhus University (GloHAU), Aarhus, Denmark"},{"name":"International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erja","family":"Chryssanthou","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Karolinska University Hospital, Solna, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Giske","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital, Solna, Stockholm, Sweden"},{"name":"Department of Clinical Microbiology, Karolinska University Hospital, Solna, Stockholm, Sweden"},{"name":"Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutet, Solna, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sch\u00f6n","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital, Solna, Stockholm, Sweden"},{"name":"Department of Biomedical and Clinical Sciences, Link\u00f6ping University, Link\u00f6ping, Sweden"},{"name":"Department of Infectious Diseases, Region \u00d6sterg\u00f6tland and Kalmar County Hospital, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8885-3320","authenticated-orcid":false,"given":"Lina Davies","family":"Forsman","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital, Solna, Stockholm, Sweden"},{"name":"Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, Solna, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"R1-20250306","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/22221751.2019.1637702","article-title":"Comprehensive subspecies identification of 175 nontuberculous mycobacteria species based on 7547 genomic profiles","volume":"8","author":"Matsumoto","year":"2019","journal-title":"Emerg Microbes Infect"},{"key":"R2-20250306","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.meegid.2017.10.013","article-title":"The new phylogeny of the genus Mycobacterium:The old and the news","volume":"56","author":"Tortoli","year":"2017","journal-title":"Infect Genet Evol"},{"key":"R4-20250306","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijid.2022.10.013","article-title":"Global trends of pulmonary infections with nontuberculous mycobacteria:A systematic review","volume":"125","author":"Dahl","year":"2022","journal-title":"Int J Infect Dis"},{"key":"R5-20250306","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0033-1333573","article-title":"Underlying host risk factors for nontuberculous mycobacterial lung disease","volume":"34","author":"Chan","year":"2013","journal-title":"Semin Respir Crit Care Med"},{"key":"R6-20250306","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/genes11060589","article-title":"The changing epidemiology of cystic fibrosis:Incidence, survival and impact of the CFTR gene discovery","volume":"11","author":"Scotet","year":"2020","journal-title":"Genes (Basel)"},{"key":"R7-20250306","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-2600(17)30293-X","article-title":"Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015:A systematic analysis for the global burden of disease study 2015","volume":"5","year":"2017","journal-title":"Lancet Respir Med"},{"key":"R8-20250306","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12931-022-02023-8","article-title":"Increasing prevalence and burden of bronchiectasis in urban Chinese adults, 2013-2017:A nationwide population-based cohort study","volume":"23","author":"Feng","year":"2022","journal-title":"Respir Res"},{"key":"R9-20250306","first-page":"27","article-title":"Infection sources of a common non-tuberculous mycobacterial pathogen, Mycobacterium avium complex","volume":"4","author":"Nishiuchi","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"R10-20250306","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease:An official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R11-20250306","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jac\/dkr578","article-title":"Mycobacterium abscessus:A new antibiotic nightmare","volume":"67","author":"Nessar","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R12-20250306","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.chest.2017.04.166","article-title":"Microbiological and clinical outcomes of treating non-Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease:A systematic review and meta-analysis","volume":"152","author":"Diel","year":"2017","journal-title":"Chest"},{"key":"R13-20250306","doi-asserted-by":"crossref","first-page":"1801991","DOI":"10.1183\/13993003.01991-2018","article-title":"M ycobacterium abscessus pulmonary disease:Individual patient data meta-analysis","volume":"54","author":"Kwak","year":"2019","journal-title":"Eur Respir J"},{"key":"R14-20250306","doi-asserted-by":"crossref","first-page":"FSO438","DOI":"10.2144\/fsoa-2019-0098","article-title":"A review on bacterial resistance to carbapenems:Epidemiology, detection and treatment options","volume":"6","author":"Elshamy","year":"2020","journal-title":"Future Sci OA"},{"key":"R15-20250306","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems:Past, present, and future","volume":"55","author":"Papp-Wallace","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-20250306","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2958.2012.08199.x","article-title":"Meropenem inhibits D, D-carboxypeptidase activity in Mycobacterium tuberculosis","volume":"86","author":"Kumar","year":"2012","journal-title":"Mol Microbiol"},{"key":"R17-20250306","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1128\/AAC.00665-12","article-title":"Inactivation of Mycobacterium tuberculosis l, d-transpeptidase LdtMt by carbapenems and cephalosporins","volume":"56","author":"Dub\u00e9e","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-20250306","doi-asserted-by":"crossref","first-page":"e00866","DOI":"10.1128\/AAC.00866-17","article-title":"Mycobacterium abscessus l, d-transpeptidases are susceptible to inactivation by carbapenems and cephalosporins but not penicillins","volume":"61","author":"Kumar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-20250306","doi-asserted-by":"crossref","first-page":"112829","DOI":"10.1016\/j.ejmech.2020.112829","article-title":"b-lactam antibiotics:An overview from a medicinal chemistry perspective","volume":"208","author":"Lima","year":"2020","journal-title":"Eur J Med Chem"},{"key":"R20-20250306","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/iub.1875","article-title":"Have we realized the full potential of b-lactams for treating drug-resistant TB?","volume":"70","author":"Story-Roller","year":"2018","journal-title":"IUBMB Life"},{"key":"R21-20250306","doi-asserted-by":"crossref","first-page":"11998","DOI":"10.1021\/bi701506h","article-title":"Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate","volume":"46","author":"Hugonnet","year":"2007","journal-title":"Biochemistry"},{"key":"R22-20250306","doi-asserted-by":"crossref","first-page":"e02440","DOI":"10.1128\/AAC.02440-16","article-title":"Inhibition of the b-Lactamase Bla (Mab) by avibactam improves the in vitro and in vivo efficacy of imipenem against Mycobacterium abscessus","volume":"61","author":"Lefebvre","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-20250306","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmi.2023.02.007","article-title":"Towards clinical breakpoints for non-tuberculous mycobacteria \u2013Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution","volume":"29","author":"Fr\u00f6berg","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"R26-20250306","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1080\/14656566.2019.1660772","article-title":"The latest advances in b-lactam\/b-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections","volume":"20","author":"Papp-Wallace","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"R27-20250306","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa2105462","article-title":"Oral tebipenem pivoxil hydrobromide in complicated urinary tract infection","volume":"386","author":"Eckburg","year":"2022","journal-title":"N Engl J Med"},{"key":"R28-20250306","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1586\/14787210.5.2.185","article-title":"Faropenem:Review of a new oral penem","volume":"5","author":"Schurek","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R30-20250306","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.tube.2017.09.001","article-title":"Ionophore A23187 shows anti-tuberculosis activity and synergy with tebipenem","volume":"107","author":"Huang","year":"2017","journal-title":"Tuberculosis (Edinb)"},{"key":"R31-20250306","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1128\/AAC.03461-14","article-title":"Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable b-lactam antibiotic","volume":"59","author":"Dhar","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R32-20250306","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1128\/AAC.01158-15","article-title":"Carbapenems and rifampin exhibit synergy against Mycobacterium tuberculosis and Mycobacterium abscessus","volume":"59","author":"Kaushik","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R33-20250306","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1093\/jac\/dkx152","article-title":"In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis","volume":"72","author":"Kaushik","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R34-20250306","first-page":"379","article-title":"Impact of relebactam-mediated inhibition of Mycobacterium abscessus BlaMab b-lactamase on the in vitro and intracellular efficacy of imipenem","volume":"75","author":"Le Run","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"R36-20250306","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/48.suppl_1.5","article-title":"Determination of minimum inhibitory concentrations","volume":"48","author":"Andrews","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"R37-20250306","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/pathogens10020165","article-title":"The minimum inhibitory concentration of antibiotics:Methods, interpretation, clinical relevance","volume":"10","author":"Kowalska-Krochmal","year":"2021","journal-title":"Pathogens"},{"key":"R38-20250306","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dkq037","article-title":"Editorial:Assessing the antimicrobial susceptibility of bacteria obtained from animals","volume":"65","author":"Schwarz","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R39-20250306","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nprot.2007.521","article-title":"Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances","volume":"3","author":"Wiegand","year":"2008","journal-title":"Nat Protoc"},{"key":"R40-20250306","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/AAC.01035-15","article-title":"In vitro activity of b-lactams in combination with b-lactamase inhibitors against multidrug-resistant Mycobacterium tuberculosis isolates","volume":"60","author":"Zhang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R41-20250306","doi-asserted-by":"crossref","first-page":"e0067422","DOI":"10.1128\/spectrum.00674-22","article-title":"Uncovering beta-lactam susceptibility patterns in clinical isolates of Mycobacterium tuberculosis through whole-genome sequencing","volume":"10","author":"Oliven\u00e7a","year":"2022","journal-title":"Microbiol Spectr"},{"key":"R42-20250306","first-page":"3579832","article-title":"In vitro activity of b-lactams in combination with b-lactamase inhibitors against Mycobacterium tuberculosis clinical isolates","volume":"2018","author":"Li","year":"2018","journal-title":"Biomed Res Int"},{"key":"R43-20250306","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1128\/AAC.03539-14","article-title":"In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with b-lactamase inhibitors","volume":"58","author":"Horita","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R44-20250306","first-page":"235","article-title":"Activities of biapenem against Mycobacterium tuberculosis in macrophages and mice","volume":"32","author":"Guo","year":"2019","journal-title":"Biomed Environ Sci"},{"key":"R45-20250306","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12866-020-01954-w","article-title":"Ertapenem and faropenem against Mycobacterium tuberculosis: In vitro testing and comparison by macro and microdilution","volume":"20","author":"Gonzalo","year":"2020","journal-title":"BMC Microbiol"},{"key":"R46-20250306","article-title":"Ertapenem and faropenem for the treatment of drug resistant tuberculosis","author":"Satta","year":"2018","journal-title":"POSTER 2447-IDweek UCL"},{"key":"R47-20250306","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3390\/antibiotics11081070","article-title":"Are the newer carbapenems of any value against tuberculosis","volume":"11","author":"Gonzalo","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"R48-20250306","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/cid\/ciw474","article-title":"A faropenem, linezolid, and moxifloxacin regimen for both drug-susceptible and multidrug-resistant tuberculosis in children:FLAME path on the Milky Way","volume":"63","author":"Deshpande","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R49-20250306","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1128\/AAC.00023-13","article-title":"In vitro and in vivo efficacy of b-lactams against replicating and slowly growing\/nonreplicating Mycobacterium tuberculosis","volume":"57","author":"Solapure","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R50-20250306","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ijid.2021.01.062","article-title":"Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration","volume":"104","author":"Gumbo","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R51-20250306","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ebiom.2016.05.041","article-title":"Paradoxical hypersusceptibility of drug-resistant Mycobacteriumtuberculosis to b-lactam antibiotics","volume":"9","author":"Cohen","year":"2016","journal-title":"EBioMedicine"},{"key":"R52-20250306","first-page":"427","article-title":"In vitro evaluation of linezolid and meropenem against clinical isolates of multi drug resistant tuberculosis by mycobacterial growth indicator tube (MGIT) 960","volume":"25","author":"Mirza","year":"2015","journal-title":"J Coll Physicians Surg Pak"},{"key":"R53-20250306","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0962-8479(92)90145-A","article-title":"In vitro activity of meropenem and imipenem against mycobacteria:Development of a daily antibiotic dosing schedule","volume":"73","author":"Watt","year":"1992","journal-title":"Tuber Lung Dis"},{"key":"R54-20250306","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/jac\/dks395","article-title":"Is there a place for b-lactams in the treatment of multidrug-resistant\/extensively drug-resistant tuberculosis?Synergy between meropenem and amoxicillin\/clavulanate","volume":"68","author":"Gonzalo","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R55-20250306","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1126\/science.1167498","article-title":"Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis","volume":"323","author":"Hugonnet","year":"2009","journal-title":"Science"},{"key":"R56-20250306","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1128\/AAC.00171-15","article-title":"Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis","volume":"59","author":"Davies Forsman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R57-20250306","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/jac\/dkx022","article-title":"Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic\/pharmacodynamic parameters","volume":"72","author":"Cavanaugh","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R58-20250306","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4046\/trd.2021.0175","article-title":"Susceptibility of b-lactam antibiotics and genetic mutation of drug-resistant Mycobacterium tuberculosis isolates in Korea","volume":"85","author":"Park","year":"2022","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"R59-20250306","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1021\/acsinfecdis.2c00229","article-title":"Structure-activity relationship of penem antibiotic side chains used against mycobacteria reveals highly active compounds","volume":"8","author":"Batchelder","year":"2022","journal-title":"ACS Infect Dis"},{"key":"R60-20250306","first-page":"e02623","article-title":"In vitro activity of the new b-lactamase inhibitors relebactam and vaborbactam in combination with b-lactams against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R61-20250306","first-page":"e00733","article-title":"New b-lactamase inhibitors nacubactam and zidebactam improve the in vitro activity of b-lactam antibiotics against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R62-20250306","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2217\/fmb-2016-0234","article-title":"Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus","volume":"12","author":"Kaushik","year":"2017","journal-title":"Future Microbiol"},{"key":"R63-20250306","doi-asserted-by":"crossref","first-page":"e02545","DOI":"10.1128\/AAC.02545-20","article-title":"b-lactam combinations that exhibit synergy against Mycobacteroides abscessus clinical isolates","volume":"65","author":"Story-Roller","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R64-20250306","first-page":"e02613","article-title":"Select b-lactam combinations exhibit synergy against Mycobacterium abscessus in vitro","volume":"63","author":"Story-Roller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R65-20250306","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/JCM.00298-16","article-title":"In vitro comparison of ertapenem, meropenem and imipenem against isolates of rapidly growing mycobacteria and Nocardia by use of broth microdilution and Etest","volume":"54","author":"Brown-Elliott","year":"2016","journal-title":"J Clin Microbiol"},{"key":"R66-20250306","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12879-017-2298-8","article-title":"Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan","volume":"17","author":"Hatakeyama","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R67-20250306","doi-asserted-by":"crossref","first-page":"e0192821","DOI":"10.1128\/Spectrum.01928-21","article-title":"Minimum inhibitory concentrations before and after antibacterial treatment in patients with Mycobacterium abscessus pulmonary disease","volume":"9","author":"Fujiwara","year":"2021","journal-title":"Microbiol Spectr"},{"key":"R68-20250306","doi-asserted-by":"crossref","first-page":"106669","DOI":"10.1016\/j.ijantimicag.2022.106669","article-title":"In vitro effects of diazabicyclooctane b-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex","volume":"60","author":"Misawa","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"R69-20250306","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s10156-002-0176-8","article-title":"Successful treatment with faropenem and clarithromycin of pulmonary Mycobacterium abscessus infection","volume":"8","author":"Tanaka","year":"2002","journal-title":"J Infect Chemother"},{"key":"R70-20250306","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1089\/mdr.2015.0134","article-title":"In vitro antimicrobial susceptibility of nontuberculous mycobacteria in Iran","volume":"22","author":"Heidarieh","year":"2016","journal-title":"Microb Drug Resist"},{"key":"R71-20250306","doi-asserted-by":"crossref","first-page":"e00098","DOI":"10.1128\/AAC.00098-20","article-title":"Insights into the l, d-transpeptidases and d, d-carboxypeptidase of Mycobacterium abscessus:Ceftaroline, imipenem, and novel diazabicyclooctane inhibitors","volume":"64","author":"Dousa","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R72-20250306","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.2147\/IDR.S252485","article-title":"Antimicrobial susceptibility of Mycobacterium abscessus complex clinical isolates from a Chinese tertiary hospital","volume":"13","author":"Guo","year":"2020","journal-title":"Infect Drug Resist"},{"key":"R73-20250306","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0929-6646(08)60088-1","article-title":"Antimicrobial resistance of rapidly growing mycobacteria in Western Taiwan:SMART program 2002","volume":"107","author":"Huang","year":"2008","journal-title":"J Formos Med Assoc"},{"key":"R74-20250306","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.2147\/IDR.S267552","article-title":"Zinc chelator N, N, N', N'-Tetrakis (2-Pyridylmethyl) Ethylenediamine reduces the resistance of Mycobacterium abscessus to imipenem","volume":"13","author":"He","year":"2020","journal-title":"Infect Drug Resist"},{"key":"R75-20250306","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/jac\/dkz523","article-title":"Repurposing drugs for treatment of Mycobacterium abscessus:A view to a kill","volume":"75","author":"Gumbo","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R76-20250306","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/jac\/dku510","article-title":"b-lactamase inhibition by avibactam in Mycobacterium abscessus","volume":"70","author":"Dub\u00e9e","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R77-20250306","doi-asserted-by":"crossref","first-page":"O297","DOI":"10.1111\/1469-0691.12405","article-title":"In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex","volume":"20","author":"Lavollay","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R78-20250306","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/jac\/dkx284","article-title":"Effect of b-lactamase production and b-lactam instability on MIC testing results for Mycobacterium abscessus","volume":"72","author":"Rominski","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R79-20250306","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3346\/jkms.2007.22.5.784","article-title":"Evaluation of the broth microdilution method using 2,3-diphenyl-5-thienyl- (2)-tetrazolium chloride for rapidly growing mycobacteria susceptibility testing","volume":"22","author":"Lee","year":"2007","journal-title":"J Korean Med Sci"},{"key":"R80-20250306","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijantimicag.2007.05.003","article-title":"In vitro efficacy of imipenem in combination with six antimicrobial agents against Mycobacterium abscessus","volume":"30","author":"Miyasaka","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"R81-20250306","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s42003-020-01475-2","article-title":"Development of a penem antibiotic against Mycobacteroides abscessus","volume":"3","author":"Batchelder","year":"2020","journal-title":"Commun Biol"},{"key":"R82-20250306","first-page":"73","article-title":"Evaluation of antimicrobial susceptibilities of rapidly growing mycobacteria by sensititre RAPMYCO panel","volume":"35","author":"Cavusoglu","year":"2012","journal-title":"New Microbiol"},{"key":"R83-20250306","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41598-020-57844-8","article-title":"Effect of amoxicillin in combination with imipenem-relebactam against Mycobacterium abscessus","volume":"10","author":"Lopeman","year":"2020","journal-title":"Sci Rep"},{"key":"R84-20250306","doi-asserted-by":"crossref","first-page":"e00236","DOI":"10.1128\/AAC.00236-20","article-title":"AR-12 exhibits direct and host-targeted antibacterial activity toward Mycobacterium abscessus","volume":"64","author":"Zhang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R85-20250306","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12866-020-02000-5","article-title":"The synergetic effect of imipenem-clarithromycin combination in the Mycobacteroides abscessus complex","volume":"20","author":"Takei","year":"2020","journal-title":"BMC Microbiol"},{"key":"R86-20250306","doi-asserted-by":"crossref","first-page":"4902941","DOI":"10.1155\/2018\/4902941","article-title":"In vitro susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum isolates to 30 antibiotics","volume":"2018","author":"Shen","year":"2018","journal-title":"Biomed Res Int"},{"key":"R87-20250306","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1128\/AAC.47.6.1958-1962.2003","article-title":"High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan","volume":"47","author":"Yang","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R88-20250306","doi-asserted-by":"crossref","first-page":"e02895","DOI":"10.1128\/mBio.02895-18","article-title":"Dual b-lactam combinations highly active against Mycobacterium abscessus complex in vitro","volume":"10","author":"Pandey","year":"2019","journal-title":"mBio"},{"key":"R89-20250306","doi-asserted-by":"crossref","first-page":"e02234","DOI":"10.1128\/AAC.02234-18","article-title":"In vitro synergism of rifabutin with clarithromycin, imipenem, and tigecycline against the Mycobacterium abscessus complex","volume":"63","author":"Cheng","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R90-20250306","doi-asserted-by":"crossref","first-page":"e0352921","DOI":"10.1128\/mbio.03529-21","article-title":"Inhibiting Mycobacterium abscessus cell wall synthesis:Using a novel diazabicyclooctane b-lactamase inhibitor to augment b-lactam action","volume":"13","author":"Dousa","year":"2022","journal-title":"mBio"},{"key":"R91-20250306","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jgar.2021.02.024","article-title":"Antimicrobial susceptibility profiles of Mycobacterium abscessus complex isolates from respiratory specimens in Shanghai, China","volume":"25","author":"Guo","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"R92-20250306","doi-asserted-by":"crossref","first-page":"100064","DOI":"10.1016\/j.tcsw.2021.100064","article-title":"In vitro efficacy of relebactam versus avibactam against Mycobacterium abscessus complex","volume":"7","author":"Harrison","year":"2021","journal-title":"Cell Surf"},{"key":"R93-20250306","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1080\/07853890.2022.2121984","article-title":"Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract","volume":"54","author":"He","year":"2022","journal-title":"Ann Med"},{"key":"R94-20250306","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/jac\/dkx212","article-title":"Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan","volume":"72","author":"Lee","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R95-20250306","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijid.2014.02.014","article-title":"Species identification of Mycobacterium abscessus subsp. Abscessus and Mycobacterium abscessus subsp. Bolletii using rpoB and hsp65, and susceptibility testing to eight antibiotics","volume":"25","author":"Nie","year":"2014","journal-title":"Int J Infect Dis"},{"key":"R96-20250306","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41429-020-00392-0","article-title":"Comparison of two-drug combinations, amikacin\/tigecycline\/imipenem and amikacin\/tigecycline\/clarithromycin against Mycobacteroides abscessus subsp. Abscessus using the in vitro time-kill assay","volume":"74","author":"Portell-Buj","year":"2021","journal-title":"Antibiot (Tokyo)"},{"key":"R97-20250306","doi-asserted-by":"crossref","first-page":"O1124","DOI":"10.1111\/1469-0691.12780","article-title":"In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex","volume":"20","author":"Singh","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R98-20250306","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cmi.2014.10.018","article-title":"Rapidly growing mycobacteria in Singapore, 2006-2011","volume":"21","author":"Tang","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"R99-20250306","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1128\/JCM.37.6.1676-1682.1999","article-title":"Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum","volume":"37","author":"Woods","year":"1999","journal-title":"J Clin Microbiol"},{"key":"R100-20250306","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3760\/cma.j.issn.0366-6999.20122495","article-title":"Clinical isolates of Mycobacterium abscessus in Guangzhou area most possibly from the environmental infection showed variable susceptibility","volume":"126","author":"Zhuo","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"R101-20250306","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1684-1182(10)60063-1","article-title":"Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing","volume":"43","author":"Huang","year":"2010","journal-title":"J Microbiol Immunol Infect"},{"key":"R102-20250306","doi-asserted-by":"crossref","first-page":"419392","DOI":"10.1155\/2015\/419392","article-title":"Drug susceptibility testing of 31 antimicrobial agents on rapidly growing mycobacteria isolates from China","volume":"2015","author":"Pang","year":"2015","journal-title":"Biomed Res Int"},{"key":"R103-20250306","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ijantimicag.2016.10.024","article-title":"Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria","volume":"49","author":"Li","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R104-20250306","doi-asserted-by":"crossref","first-page":"e0053622","DOI":"10.1128\/aac.00536-22","article-title":"T405, a new penem, exhibits in vivo efficacy against M. abscessus and synergy with b-lactams imipenem and cefditoren","volume":"66","author":"Rimal","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"R105-20250306","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0732-8893(87)90100-3","article-title":"Comparative in vitro activities of ampicillin, BMY 28142, and imipenem against Mycobacterium avium complex","volume":"6","author":"Cynamon","year":"1987","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R106-20250306","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1089\/mdr.2017.0286","article-title":"Activities of dual combinations of antibiotics against multidrug-resistant nontuberculous mycobacteria recovered from patients with cystic fibrosis","volume":"24","author":"Schwartz","year":"2018","journal-title":"Microb Drug Resist"},{"key":"R107-20250306","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0769-2609(88)90007-5","article-title":"Action of antituberculous and beta-lactam drugs (including imipenem) against extra- and intra-cellularly growing Mycobacterium avium-intracellulare","volume":"139","author":"Rastogi","year":"1988","journal-title":"Ann Inst Pasteur Microbiol"},{"key":"R108-20250306","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1128\/AAC.31.10.1579","article-title":"Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome","volume":"31","author":"Yajko","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"R109-20250306","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2217\/fmb-2016-0208","article-title":"Ldt (Mav2), a nonclassical transpeptidase and susceptibility of Mycobacterium avium to carbapenems","volume":"12","author":"Mattoo","year":"2017","journal-title":"Future Microbiol"},{"key":"R111-20250306","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1183\/13993003.01278-2015","article-title":"Ertapenem in the treatment of multidrug-resistant tuberculosis:First clinical experience","volume":"47","author":"Tiberi","year":"2016","journal-title":"Eur Respir J"},{"key":"R112-20250306","first-page":"177","article-title":"Beta-lactamase activity in mycobacteria including Mycobacterium avium and suppression of their growth by a beta-lactamase-stable antibiotic","volume":"81","author":"Prabhakaran","year":"1995","journal-title":"Microbios"},{"key":"R113-20250306","doi-asserted-by":"crossref","first-page":"i36","DOI":"10.1093\/jac\/dkx306","article-title":"The discovery of ceftazidime\/avibactam as an anti-Mycobacterium avium agent","volume":"72","author":"Deshpande","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R114-20250306","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/dkt410","article-title":"Characterization of broad-spectrum Mycobacterium abscessus class A b-lactamase","volume":"69","author":"Soroka","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R115-20250306","doi-asserted-by":"crossref","first-page":"e00618","DOI":"10.1128\/AAC.00618-19","article-title":"Safety, pharmacokinetics, and food effect of tebipenem pivoxil hydrobromide after single and multiple ascending oral doses in healthy adult subjects","volume":"63","author":"Eckburg","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R116-20250306","doi-asserted-by":"crossref","first-page":"e00603","DOI":"10.1128\/AAC.00603-19","article-title":"Pharmacodynamics of tebipenem:New options for oral treatment of multidrug-resistant gram-negative infections","volume":"63","author":"McEntee","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R117-20250306","doi-asserted-by":"crossref","first-page":"e0145922","DOI":"10.1128\/aac.01459-22","article-title":"Activity of oral tebipenem-avibactam in a mouse model of Mycobacterium abscessus lung infection","volume":"67","author":"Negatu","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"R118-20250306","doi-asserted-by":"crossref","first-page":"115555","DOI":"10.1016\/j.diagmicrobio.2021.115555","article-title":"Phenotypic drug susceptibility testing of rapid growing mycobacteria and the issue of antibiotic stability","volume":"102","author":"Wetzstein","year":"2022","journal-title":"Diagn Microbiol Infect Diss"},{"key":"R119-20250306","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment:Facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R121-20250306","doi-asserted-by":"crossref","first-page":"e01489","DOI":"10.1128\/AAC.01489-18","article-title":"Evaluation of carbapenems for treatment of multi- and extensively drug-resistant Mycobacterium tuberculosis","volume":"63","author":"van Rijn","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R122-20250306","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/ijms17030373","article-title":"Carbapenems to treat multidrug and extensively drug-resistant tuberculosis:A Systematic Review","volume":"17","author":"Sotgiu","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R123-20250306","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMc1513236","article-title":"b-lactams against tuberculosis \u2013New trick for an old dog?","volume":"375","author":"Diacon","year":"2016","journal-title":"N Engl J Med"},{"key":"R124-20250306","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1164\/rccm.202108-1976OC","article-title":"Early bactericidal activity of meropenem plus clavulanate (with or without rifampin) for tuberculosis:The COMRADE randomized, phase 2A clinical trial","volume":"205","author":"De Jager","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"R125-20250306","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.201911-2149LE","article-title":"Optimizing b-lactams against tuberculosis","volume":"201","author":"de Jager","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R126-20250306","doi-asserted-by":"crossref","first-page":"e0234651","DOI":"10.1371\/journal.pone.0234651","article-title":"Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath:A mixed methods study on treatment outcomes and challenges","volume":"15","author":"Chavan","year":"2020","journal-title":"PLoS One"},{"key":"R127-20250306","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_131_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:55:12Z","timestamp":1787763312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_131_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":120,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_131_23","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2023-06-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}